A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT ID: NCT03525574
Last Updated: 2025-09-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
507 participants
INTERVENTIONAL
2018-10-09
2023-01-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03525548
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525444
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT04058366
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
NCT04105972
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT04043806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ELX/TEZ/IVA
Treatment Period: Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.
Extension Period: Participants from certain countries participated in extension period and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks.
ELX/TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.
IVA
Tablet for oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELX/TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.
IVA
Tablet for oral administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current participation in an investigational drug trial (other than a parent study)
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner University of Arizona Medical Center
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Miller Children's Hospital / Long Beach Memorial
Long Beach, California, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Valley Children's Hospital
Madera, California, United States
Kaiser Permanente
Oakland, California, United States
University of California Davis Medical Center
Sacramento, California, United States
UCSF Gateway Medical Center
San Francisco, California, United States
National Jewish Health
Denver, Colorado, United States
University of Florida, Shands Hospital
Gainesville, Florida, United States
Joe DiMaggio Cystic Fibrosis & Pulmonary Center
Hollywood, Florida, United States
Nemours Children's Specialty Care
Jacksonville, Florida, United States
Central Florida Pulmonary Group, PA
Orlando, Florida, United States
Nemours Children's Hospital
Orlando, Florida, United States
Tampa General Hospital Cardiac and Lung Transplant Clinic
Tampa, Florida, United States
Children's Specialty Services at North Druid Hills
Atlanta, Georgia, United States
Augusta University
Augusta, Georgia, United States
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Cystic Fibrosis Center, Children's Hospital of Illinois at OSF Saint Francis Medical Center
Peoria, Illinois, United States
The University of Kansas Medical Center
Kansas City, Kansas, United States
Tulane Medical Center
New Orleans, Louisiana, United States
Maine Medical Partners
Portland, Maine, United States
Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center
Boston, Massachusetts, United States
Harper University Hospital
Detroit, Michigan, United States
Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States
Billings Clinic Hospital
Billings, Montana, United States
Nebraska Medical Center
Omaha, Nebraska, United States
Morristown Medical Center
Morristown, New Jersey, United States
UNM Clinical and Translational Science Center
Albuquerque, New Mexico, United States
The Cystic Fibrosis Center, Mount Sinai Beth Israel
New York, New York, United States
New York Medical College
Valhalla, New York, United States
UNC Marsico Clinical Research Center
Chapel Hill, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
UC Health Holmes
Cincinnati, Ohio, United States
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Dayton Children's Hospital
Dayton, Ohio, United States
ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
Toledo, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Dell Children's Medical Center of Central Texas
Austin, Texas, United States
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Vermont Lung Center
Colchester, Vermont, United States
University of Virginia Primary Care Center
Charlottesville, Virginia, United States
Children's Hospital of the King's Daughters
Norfolk, Virginia, United States
Children's Hospital of Richmond at VCU, Children's Pavilion
Richmond, Virginia, United States
University of Washington Medical Center
Seattle, Washington, United States
West Virginia University
Morgantown, West Virginia, United States
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin, United States
CTSI Adult Translational Research Unit/Medical College of Wisconsin/Froedtert Hospital
Milwaukee, Wisconsin, United States
Women & Children's Hospital
North Adelaide, , Australia
The Royal Children's Hospital
Parkville, , Australia
Mater Misericordiae Ltd
South Brisbane, , Australia
The Children's Hospital at Westmead
Westmead, , Australia
Westmead Hospital
Westmead, , Australia
University of Graz
Graz, , Austria
Medizinische Universität Innsbruck
Innsbruck, , Austria
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, , Austria
Medizinische Universitat Wien
Vienna, , Austria
Cliniques Universitaires de Bruxelles Hopital Erasme
Brussels, , Belgium
Universitair Ziekenhuis Brussel - Campus Jette
Brussels, , Belgium
UZ Antwerpen
Edegem, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, , Belgium
University of Calgary Medical Clinic of the Foothills Medical Centre
Calgary, , Canada
McGill University Health Centre, Glen Site, Montreal Children's Hospital
Montreal, , Canada
Centre Hospitalier De L'Universite Laval
Québec, , Canada
The Hospital for Sick Children
Toronto, , Canada
British Columbia's Children's Hospital
Vancouver, , Canada
St. Paul's Hospital
Vancouver, , Canada
Fakultni Nemocnice Brno
Brno, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
Centre Hospitalier Lyon Sud
Benite Cedex, , France
Groupe Hospitaler Pellegrin, CHU De Bordeaux
Bordeaux, , France
CHU Marseille - Hopital Nord
Marseille, , France
CHU de Nice - Hopital Pasteur
Nice, , France
Hopital Cochin
Paris, , France
CHU de Rouen - Hopital Charles Nicolle
Rouen, , France
Hopital Foch (Suresnes), Hopital Foch, Adultes
Suresnes, , France
Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital
Erlangen, , Germany
Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin
Giessen, , Germany
Hannover Medical School
Hanover, , Germany
Johannes Gutenberg-Universitaet
Mainz, , Germany
Dr. von Haunersches Kinderspital
München, , Germany
Universitaetsklinikum Tuebingen Klinik fuer Kinder- und Jugendmedizin
Tübingen, , Germany
University Hospital Wuerzburg
Würzburg, , Germany
General Hospital of Attika "Sismanoglio"(Adult CF center, NHS)
Marousi, , Greece
Azienda Ospedaliero Universitaria Ospendali Riuniti
Ancona, , Italy
Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
Florence, , Italy
IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico
Genova, , Italy
Azienda Ospedaliera Universitaria Policlinico G. Martino
Messina, , Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Centro Regionale Fibrosi Cistica, A.O. Ospedale San Carlo
Potenza, , Italy
Azienda Ospedaliera di Verona-Ospedale Civile Maggiore
Verona, , Italy
Academic Medical Center
Amsterdam, , Netherlands
University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
Heidelberglaan, , Netherlands
UMC St. Radboud
Nijmegen, , Netherlands
Erasmus Medical Center
Rotterdam, , Netherlands
HagaZiekenhuis van den Haag
The Hague, , Netherlands
Karolinska Universitetssjukhuset, Huddinge
Stockholm, , Sweden
Belfast City Hospital
Belfast, , United Kingdom
Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Western General Hospital
Edinburgh, , United Kingdom
Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital
Exeter, , United Kingdom
Leeds General Infirmary
Leeds, , United Kingdom
King's College Hospital
London, , United Kingdom
Royal Manchester Children's Hospital
Manchester, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M; VX17-445-105 Study Group. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct;211(10):1901-1914. doi: 10.1164/rccm.202411-2231OC.
Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-000185-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
VX17-445-105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.